
You are currently analyzing a forecasting question to generate an outside view prediction.

The forecasting question is:
Will ALGN's market close price on 2026-02-15 be higher than its market close price on 2026-02-02?

This question's outcome will be determined by the specific criteria below. These criteria have not yet been satisfied:
This question will resolve based on the latest market close price of ALGN. If it is higher than the close price on 2026-02-02, the question will resolve to 'Yes'. The close price will be pulled from the Yahoo Finance API.

Additional fine-print:


Question metadata:
- Opened for forecasting: 2026-02-02T15:15:52Z
- Resolves: 2026-02-15T05:26:19Z

IMPORTANT: Today's date is 2026-02-02. All dates before today's date are in the PAST. All dates after today's date are in the FUTURE. Use today's date to correctly evaluate whether sources describe past events or future predictions. Any information source which refers to events before today's date of 2026-02-02 should not be considered as speculative but rather an historical document.

Historical context:

<Summary source="https://www.macrotrends.net/stocks/charts/ALGN/align-technology/stock-price-history">
# Summary of Macrotrends Article on Align Technology Stock Price History

## Key Facts and Statistics:

**Current Price Data (as of January 30, 2026):**
- Latest closing stock price: $163.03
- 52-week high: $232.20 (42.4% above current price)
- 52-week low: $122.00 (25.2% below current price)
- Average stock price for last 52 weeks: $163.22

**Historical Milestones:**
- All-time high closing price: $729.92 (September 08, 2021)

**2026 Year-to-Date Performance (partial year):**
- Year average: $167.42
- Year open: $156.03
- Year high: $172.79
- Year low: $156.03
- Year close (as of data): $163.03
- Annual % change: 4.41%

**Recent Annual Performance:**
- 2025: Closed at $156.15 (-25.11% annual change)
- 2024: Closed at $208.51 (-23.90% annual change)
- 2023: Closed at $274.00 (+29.92% annual change)
- 2022: Closed at $210.90 (-67.91% annual change)
- 2021: Closed at $657.18 (+22.98% annual change)

**Company Information:**
- Market Cap: $11.697B
- Revenue: $3.999B
- Sector: Medical
- Industry: Medical & Dental Supplies
- PE Ratio: Not explicitly stated in extracted content

**Business Description:**
The company manufactures and markets clear aligner therapy systems, intra-oral scanners, and CAD/CAM digital services for dentistry, orthodontics, and dental records storage. Has 2 operating segments: Clear Aligner (Invisalign system) and CAD/CAM Services (iTero intra-oral scanners and OrthoCad services).

The article also includes a comparison table of peer companies in the medical/dental supplies sector, ranging from McKesson (market cap $102.593B) to smaller competitors.
</Summary>

<Summary source="https://www.nasdaq.com/market-activity/stocks/algn/historical">
**Disclaimer**: The extracted content appears to be incomplete or improperly loaded. The article consists primarily of website navigation instructions and error messages rather than substantive content about ALGN stock prices or company information.

**Summary**:

This appears to be a Nasdaq page for Align Technology, Inc. (ALGN) historical quotes, but the content did not load properly. The extracted text contains only:

- Generic website navigation instructions for adding stock symbols to watchlists
- A message indicating "Our team is working diligently to resolve the issue. Thank you for your patience and understanding"
- No actual historical price data, statistics, facts, or expert opinions about ALGN

**Key Information Extracted**: None - the article does not contain any usable information relevant to forecasting ALGN's stock price movement between February 2 and February 15, 2026.
</Summary>

<Summary source="https://www.cnbc.com/quotes/ALGN">
# Summary of Article: "Check out Align Technology's stock price (ALGN) in real time"

**Source:** CNBC

**Disclaimer:** This appears to be a real-time stock quote page with limited analytical content. The data represents a snapshot from a specific moment (11:01 AM EST on what appears to be 2026-02-01 based on the background information).

## Key Facts and Statistics:

**Current Trading Data (as of 11:01 AM EST):**
- Last Price: $163.27 (+$0.24, +0.15%)
- Volume: 208,861 shares
- Open: $162.83
- Day High: $165.00
- Day Low: $161.12
- Previous Close: $163.03

**52-Week Range:**
- 52-Week High: $232.20 (reached on 02/06/25)
- 52-Week Low: $122.00 (reached on 09/25/25)

**Company Fundamentals:**
- Market Cap: $11.715 billion
- Shares Outstanding: 71.75 million
- 10-Day Average Volume: 0.83 million
- Beta: 1.84
- No dividend currently paid

**Financial Ratios (TTM = Trailing Twelve Months):**
- EPS (TTM): $5.16
- P/E Ratio (TTM): 31.64
- Forward P/E (NTM): 14.99
- EBITDA (TTM): $819.898 million
- ROE (TTM): 9.58%
- Revenue (TTM): $3.983 billion
- Gross Margin (TTM): 69.48%
- Net Margin (TTM): 9.50%
- Debt to Equity (MRQ): Not provided

**Upcoming Events:**
- Earnings Date: 02/04/2026

**Note:** No opinions or analysis are provided in this article - it is purely a data display of stock metrics and trading information.
</Summary>

<Summary source="https://orthodonticproductsonline.com/industry-news/company-news/align-reports-q1-2025-revenue-decline-despite-invisalign-growth/">
# Summary: Align Technology Q1 2025 Earnings Report

**Key Financial Facts (Q1 2025):**
- Total revenues: $979.3 million (down 1.6% sequentially, down 1.8% year-over-year)
- Foreign exchange impact: -$21.4 million vs. prior quarter, -$31.1 million vs. same quarter last year
- Clear Aligner revenues: $796.8 million (down 2.5% year-over-year despite 6.2% increase in case volume)
- Clear aligner volume: 642,300 cases (up 2.2% sequentially)
- Teen/growing patient cases: 225,800 cases (up 4.5% sequentially, up 13.3% year-over-year)
- Imaging Systems and CAD/CAM Services segment: $182.4 million (up 1.2% vs. Q1 2024)
- Company milestone: 20 million Invisalign patients treated

**Tariff and Manufacturing Information:**
- U.S. market clear aligners manufactured in Mexico (USMCA compliant, currently exempt from tariffs under April 2, 2025 Executive Order)
- China production exclusively for Chinese market (not exported to U.S.)
- Intraoral scanners manufactured in Israel
- Current 10% U.S. tariff on Israeli imports estimated to cost ~$1 million monthly (factored into Q2 and full-year 2025 guidance)
- Company notes U.S.-Mexico tariff environment "remains fluid and subject to change"

**Q2 2025 Guidance (from company):**
- Expected revenues: $1.05-$1.07 billion (sequential growth)
- Clear Aligner volume and average selling prices both expected to increase
- GAAP and non-GAAP operating margins expected to improve sequentially by ~3 points

**Full Year 2025 Guidance (from company):**
- Clear Aligner volume growth: mid-single digits year-over-year
- Average selling prices: projected to decline due to product mix and emerging market expansion
- Systems and Services revenue: expected to grow faster than Clear Aligner revenue
- Overall revenue growth: 3.5%-5.5% at current spot rates
- GAAP operating margin: ~2 points higher than 2024
- Non-GAAP operating margin: ~22.5%
- Capital expenditures: $100-$150 million

**Source Attribution:** Joe Hogan, Align Technology President and CEO, provided statement about the 20 million patient milestone celebration.
</Summary>

<Summary source="https://www.fool.com/investing/2025/10/30/why-align-technology-stock-popped-today/">
# Summary of Article: "Why Align Technology Stock Popped Today"

**Source:** The Motley Fool  
**Date:** October 30, 2025  
**Author:** Rich Smith

## Key Facts and Statistics:

- **Stock Performance:** ALGN stock jumped 8% through 10:40 a.m. ET on the day of the article, following Q3 earnings release
- **Stock had declined 35% over the past year** (as of article date)

### Q3 2025 Earnings Results:
- **Adjusted earnings:** $2.61 per share (beat analyst expectations of $2.41)
- **Revenue:** $995.7 million (beat analyst expectations of $976.3 million)
- **Sales growth:** Less than 2% year-over-year
- **Sequential sales:** Declined from Q2 to Q3
- **GAAP earnings:** Only $0.78 per share (significantly lower than adjusted figures)

### Cash Flow Data (First 9 months of 2025):
- **Operating cash flow:** $370 million (down 18% from prior year period)
- **Note:** Free cash flow not fully specified due to lack of capital spending data in the article

### Valuation Metrics:
- **Market capitalization:** $10.2 billion
- **Trailing profit:** $378 million
- **Trailing free cash flow:** $540 million
- **P/E ratio:** 27
- **Price-to-free-cash-flow ratio:** Less than 18.9

## Opinions:

### From Author (Rich Smith - The Motley Fool):
- Most of the sales increase appeared to be explained by favorable foreign exchange rates
- Analysts polled by S&P Global Market Intelligence see 10% long-term growth as likely
- Earnings are currently still falling
- **Author's conclusion:** "Align stock looks like a sell to me"
</Summary>

<Summary source="https://finance.yahoo.com/news/heres-align-technology-placed-ahead-130200455.html">
# Summary: Align Technology Q4 2025 Earnings Preview

**Key Facts and Statistics:**

- **Earnings Release Date:** February 4, 2026 (after market close)
- **Last Quarter Performance (Q3 2025):** Adjusted EPS of $2.61, which beat consensus by 10.1%
- **Historical Performance:** Beat earnings estimates in 3 of the last 4 quarters, with average surprise of 3.75%

**Q4 2025 Consensus Estimates:**
- Revenue: $1.03 billion (3.9% year-over-year growth)
- EPS: $2.99 per share (22.5% year-over-year increase)
- Estimate trend: EPS estimate unchanged at $2.99 in past 60 days

**Expected Q4 Performance Drivers:**

*Clear Aligner Segment:*
- Expected higher Clear Aligner volumes, particularly in EMEA, APAC, and Latin America regions
- Growth anticipated in both orthodontist and general practitioner dentist channels
- Volume growth expected across adults, teens, and kids segments
- Continued strength from Dental Service Organizations (DSOs)
- Q3 2025 marked all-time high for doctors submitting Invisalign case starts for teens and kids, potentially extending into Q4

*Product Contributions:*
- Strong contributions expected from:
  - Invisalign First
  - DSP touch-up cases
  - Invisalign Palatal Expander
  - Retention products
  - Continued shift from non-comprehensive Clear Aligner products

*Q4 Developments:*
- Rolled out Invisalign System with mandibular advancement featuring occlusal blocks in Thailand and Philippines
- Partnership with Healthcare Finance Direct expected to increase treatment affordability and boost enrollment
- Introduction of new treatment planning tools, including Clin Check Live Plan (reduces treatment planning cycle from days to minutes)

**Source Attribution:** Article by Zacks Equity Research, published January 29, 2026 on Yahoo Finance
</Summary>

<Agent_report>
Query: Summarize Align Technology’s financial performance 2023-2025, key drivers, Q4 2025 earnings results and guidance, analyst targets, and near-term catalysts expected before Feb 15 2026
Align Technology (NASDAQ: ALGN) is emerging from a period of slower post-pandemic recovery that has stretched across 2023-2025.  Based on the public information available through 30 January 2026, the picture is as follows.

1.  Financial performance 2023-2024  
• FY 2023 (base year): Management has not yet issued a stand-alone 2023 press release in the sources provided, but FY 2024 commentary gives the comparison point.  DentalMarketInsights notes FY 2023 revenue of $3.86 billion and GAAP net income of $445 million, with a GAAP operating margin of 16.7 % [DentalMarketInsights, 3-Apr-2025].  
• FY 2024: Revenue rose 3.5 % to $4.00 billion.  Clear Aligner revenue increased a modest 1 % to $3.23 billion on 3.5 % case-volume growth (2.49 million cases), while Imaging Systems & CAD/CAM revenue jumped 16 % to $768.9 million.  GAAP net income slipped 5 % to $421 million, reflecting FX headwinds (~$38 million) and restructuring costs; non-GAAP net income was $700 million.  Non-GAAP operating margin edged up to 21.8 % despite a GAAP margin compression to 15.2 % [DentalMarketInsights; OrthodonticProducts, 6-Feb-2025].  
• Key 2024 drivers  
  – Volume growth outside the U.S. (EMEA, APAC, LATAM) with teen and kid segments particularly strong.  
  – Systems & Services strength led by iTero Lumina scanner upgrades.  
  – FX headwinds and a mix shift to lower-priced, non-comprehensive products that pressured ASPs.  
  – Successful settlement of a UK VAT dispute, resulting in a $100 million refund in Q4 2024 and removal of a potential liability for sales through mid-October 2023 [TheTranscript, Q4 2024 call].

2.  2025 performance year-to-date and full-year outlook  
• Through nine months of 2025, revenue is tracking just under $3.0 billion (derived from the $995.7 million Q3 print plus prior quarters), up low-single digits year-over-year, with clear aligner volumes up mid-single digits and Systems & Services still outgrowing the core aligner segment [Motley Fool, 30-Oct-2025].  
• Q3 2025 highlights: revenue $995.7 million (+<2 % y/y) and non-GAAP EPS $2.61 vs. $2.41 consensus; GAAP EPS was $0.78 because of higher stock-based comp and restructuring charges [Motley Fool].  Operating cash flow for the first nine months fell 18 % to $370 million, reflecting heavier capex and working-capital uses.  
• Management raised Q4 2025 revenue guidance to $1.03-1.05 billion and projected mid-single-digit clear aligner volume growth, implying full-year revenue of roughly $4.0-4.1 billion—flat to slightly up on 2024 [Yahoo Finance/Barchart, 7-Jan-2026].  

3.  Q4 2025 earnings event and guidance  
• Release date: 4 February 2026 after market close; webcast to follow [SimplyWallSt, 9-Jan-2026].  
• Consensus expectations (Zacks/Yahoo): revenue $1.03 billion (+3.9 % y/y) and non-GAAP EPS $2.99 (+22 % y/y).  Street EPS for full-year 2025 stands at $8.18 (+16.7 % y/y) [Yahoo Finance/Zacks, 29-Jan-2026].  
• Management commentary heading into the print stresses:  
  – Continued volume momentum in EMEA, APAC & LATAM; record doctor participation in teen/kid cases.  
  – Ongoing mix shift toward non-comprehensive products and retention (DSP touch-ups, Vivera).  
  – Benefits from the March 2025 3 % list-price hike offset by elimination of $10-$15 order fees (net neutral to ASPs) [OrthodonticProducts].  
  – Tariff watch: company still sees risk of a 25 % U.S. tariff on Mexican aligner imports, but maintains that Mexico remains the lowest-cost option even if tariffs are imposed [OrthodonticProducts].

4.  Analyst targets & sentiment  
• Average 12-month price target ranges from ~$171 to $190, implying ~2-40 % upside from the recent $135-140 share price.  The dispersion is wide: highs up to $235; lows near $140 [Benzinga, 26-Nov-2025; Nasdaq/Morgan Stanley note, 21-Oct-2025].  
• Ratings: “Moderate Buy” with 8-9 strong buys, 6 holds, 1 sell out of ~15 analysts [Yahoo Finance/Barchart, 7-Jan-2026].  Morgan Stanley, for example, remains “Equal-Weight” with a $190 PT.  Concerns center on slow U.S. recovery, ASP pressure and competition; positives are international demand, scanner ecosystem growth and balance-sheet strength (no debt, ~$1 billion cash).

5.  Near-term catalysts before 15 Feb 2026  
Confirmed, date-certain  
• Q4 2025 and FY 2025 earnings call (4 Feb 2026) – first look at holiday-period demand and 2026 guidance.  
• Margin-expansion roadmap update – management is targeting ≥100 bp operating-margin lift in 2026, partly from the new “0 × 3” three-year treatment suite without built-in refinements and residual savings from 2024-2025 restructuring [SimplyWallSt, 26-Jan-2026].  
Expected/possible  
• Tariff decision by the U.S. on Mexican imports – could reshape COGS or require sourcing shifts.  
• Additional UK court ruling on remaining £7 million VAT dispute (company expected a first-half-2024 decision; outcome could still be disclosed in early 2026 if delayed) [TheTranscript].  
• Commercial launch milestones for Invisalign Palatal Expander, mandibular-advancement features and expanded iTero Lumina roll-out to restorative dentists (restorative version scheduled for March 2025; full market penetration updates likely on the February call).  
• Further adoption metrics for the AI-enabled ClinCheck Live Plan and Healthcare Finance Direct partnership, both highlighted by analysts as volume catalysts [FinancialContent, 5-Nov-2025; Zacks preview].  
• Potential follow-on litigation or regulatory resolutions: the $31.75 million antitrust settlement with Smile Direct Club closed in mid-2025; investors will watch for any incremental legal provisions or FTC scrutiny [AInvest].

6.  Key operating drivers and risks heading into 2026  
Positives  
• Undisputed clear-aligner market leadership (~60 % share) and unmatched digital workflow (iTero + ClinCheck + exocad) create switching-cost moat.  
• Systems & Services segment (scanners, CAD/CAM) is outgrowing the core and carries higher incremental margin, providing diversification.  
• Balance sheet: ~$1 billion cash, no debt, giving capacity for buybacks (>$350 million in 2024) and tuck-in tech investments (e.g., $30 million in Smile Doctors DSO).  
Headwinds  
• Price/ASP pressure due to mix shift, stronger USD and emerging low-cost competitors in China & direct-to-consumer channels.  ASPs fell $55 y/y in Q4 2024 despite price increases [TheTranscript].  
• Volume-to-revenue divergence: Q1 FY 2025 volumes up 6.2 % yet aligner revenue down 2.5 % [AInvest].  
• Macro sensitivity: orthodontic starts are discretionary and correlate with consumer confidence, still soft in U.S. GP channel [FinancialContent Q&A; Motley Fool].  
• Tariff and FX uncertainty could swing COGS and reported growth by several percentage points.  

7.  Remaining information gaps  
a)  Detailed FY 2023 statement by segment, region and cash-flow line items is not provided in the current sources.  
b)  Actual Q4 2025 results and the company’s formal FY 2026 revenue/earnings guidance will only be known after 4 Feb 2026.  
c)  Quantitative impact of the “0 × 3 Suite” margin initiative (expected 2026) is not yet disclosed beyond the ≥100 bp target.  
d)  Updated status/timing of any U.S.-Mexico tariff ruling has not been publicly confirmed.  

These gaps could be filled by reviewing ALGN’s 2023 Form 10-K and its upcoming Q4 2025 earnings materials, plus trade-policy announcements.  Apart from those missing items, the available data are sufficient to frame a near-term investment view and understand the catalysts through mid-February 2026.</Agent_report>


The information has been sourced from the internet/language models (for agent reports), so it is advisable to exercise healthy skepticism at your discretion.

Your analysis should have the following components, refering the above historical context:
(a) Source analysis: Briefly summarize each information source (either web article or Agent report), evaluate source quality and data.
**Opinions are commonplace in writing. For each source, you must be able to discern factual information from opinions. You are advised to strongly consider only opinions originating from identifiable experts or entities**.
(b) Reference class analysis: Identify a few possible reference classes and evaluate respective suitabilities to the forecasting question. If applicable, choose the most suitable one.
(c) Timeframe analysis: State the prediction timeframe (e.g., how many days/months from now?) and examine historical patterns over similar periods
(d) Justification: Integrate the above factors with other points you found relevant to write a justification for your outside view prediction.

You are free to include other components to deepen the analysis, at your discretion.

Subsequently, calibrate your outside view prediction, considering:
(a) You aim to predict the true probability of an event occuring, not a hedged or overconfident projection of your beliefs.
(b) Is there a rough figure in the sources you can tether your prediction to?
(c) Small differences in probabilities can be significant: 90% is a 9:1 odds and 99% is a 99:1 odds.

Format you answer as below:

Analysis:
{Insert your analysis here}

Outside view calibration:
{Insert your calibration of your outside view prediction here.}

Outside View Prediction:
[Provide your outside view prediction here to a 1% significance. It is not necessary for the prediction to be a neat multiple of 5%.]
